Bio Saga Blog - A Chronicle of Life Sciences & Informatics

For Indian laboratories, the decision to implement  informatics applications that support compliance with 21 CFR Part 11 delivers multiple benefits. They are protecting their access to regulated markets in the US and other countries while implementing electronic processes and procedures that can reduce costs while enhancing their ability to deliver world class results.

PerkinElmer is pleased to announce that today it completed the acquisition of Caliper Life Sciences, an exciting milestone in PerkinElmer’s evolution. The purchase, announced in September . Bringing Caliper into PerkinElmer will significantly strengthen leadership position in the growing area of personalized medicine, providing pharmaceutical companies and clinicians with the tools and knowledge they need to enable individualized diagnoses and treatments. PKI's work moving ahead in this emerging field will be made possible by an outstanding team of people from Caliper and PerkinElmer collaborating together to leverage the combined power of their knowledge and expertise to deliver insight-driven innovations. Bio-discovery and Caliper will combine to form PerkinElmer’s new Life Sciences & Technology (LST) Strategic Business Element (SBE). In a statement today, Robert Friel, chairman and CEO of PerkinElmer, said that he is confident that joining together these two organization...

PerkinElmer reported after the close of the market on Thursday that revenues in the third quarter rose 8 percent year over year, but it missed analyst estimates on the top line. Total revenues in the quarter ended Oct. 2 rose to $453.7 million, compared to $419.1 million a year ago but fell short of Wall Street estimates of $469.6 million. On an organic basis, revenues were up 4 percent year over year. The firm has made a number of purchases throughout 2011 and in the quarter those acquisitions contributed more than $20 million to the top line, CFO Frank Wilson said on a conference call after the release of the company's earnings results. The Human Health segment grew revenues to $207.4 million, up 7 percent from $194.5 million a year ago, while Environmental Health climbed to $246.3 million, a 10 percent increase from $224.6 million a year ago. On the conference call, Chairman and CEO Robert Friel said that during the quarter, growth was seen across all major geographies and most ...

The Department of Energy's Joint Genome Institute has chosen 41 research projects out of 152 applicants to use its sequencing services under its 2012 Community Sequencing Program, JGI said Thursday. Researchers for this year's CSP program, which provides the scientific community with access to JGI's high-throughput sequencing technologies, proposed projects to study plant-microbe interactions, how microbes are involved in carbon capture and greenhouse gas emission, and metagenomics. “These selections truly take advantage of the DOE JGI’s massive-scale sequencing and data analysis capabilities,” DOE JGI Director Eddy Rubin said in a statement.  “The projects span the globe and the unexplored branches of the tree of life, and promise to yield a better understanding of the interplay between climate, ecosystem, and organism.  Still other projects are targeting improvements in biofuel feedstock production, focusing on the potential of microorganisms to improve feedstock growth a...

The Centre for Applied Genomics (TCAG) at the Hospital for Sick Children in Toronto has reeled in C$5.1 million (US$5 million) from the Ontario Genomics Institute to support its operations, OGI said today. TCAG provides a range of core services including gene and genome sequencing; microarrays and genotyping; cytogenomics and biobanking; and statistical and informational services. The two years of funding was awarded under the Genome Canada Science and Technology Innovation Centre Competition. TCAG was founded in 1998 and it provides research support to labs involved in a wide array of genomic disciplines including human health, agriculture, and plant and animal studies.